MODAFINIL | A207196 | APPCO PHARMA LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Appco Pharma LLC FDA-2026-P-8559 Appco Pharma LLC filed a suitability petition with the FDA requesting a determination of whether diethylpropion is suitable for inclusion in an abbreviated new drug application for a controlled-release formulation. The petitioner seeks confirmation that the agency would accept an ANDA for diethylpro | Suitability | 2026-08-04 | Open | Appco Pharma LLC |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.3526
per ea
Lowest NADAC/Unit
$0.2539
per ea
Brand NDCs
0
Generic NDCs
6
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 23155060503MODAFINIL 200 MG TABLET | $0.3526 | EA | Generic | — | 2026-10-21 |
| 23155060509MODAFINIL 200 MG TABLET | $0.3526 | EA | Generic | — | 2026-10-21 |
| 23155086203MODAFINIL 200 MG TABLET | $0.3526 | EA | Generic | — | 2026-10-21 |
| 23155086209MODAFINIL 200 MG TABLET | $0.3526 | EA | Generic | — | 2026-10-21 |
| 23155060403MODAFINIL 100 MG TABLET | $0.2539 | EA | Generic | — | 2026-10-21 |
| 23155060409MODAFINIL 100 MG TABLET | $0.2539 | EA | Generic | — | 2026-10-21 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.